ANGO - AngioDynamics, Inc.
| Previous Close | 12.81 |
| Open | 12.81 |
| Bid | 11.27 x 1100 |
| Ask | 14.89 x 800 |
| Day's Range | 12.59 - 12.83 |
| 52 Week Range | 12.59 - 25.48 |
| Volume | 132,199 |
| Avg. Volume | 302,504 |
| Market Cap | 478.975M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | 8.66 |
| EPS (TTM) | 1.47 |
| Earnings Date | Mar 30, 2020 - Apr 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.50 |
- Simply Wall St.
Calculating The Intrinsic Value Of AngioDynamics, Inc. (NASDAQ:ANGO)
Today we will run through one way of estimating the intrinsic value of AngioDynamics, Inc. (NASDAQ:ANGO) by estimating...
- Zacks
AngioDynamics (ANGO) Down 10.4% Since Last Earnings Report: Can It Rebound?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Stephen Trowbridge to the role of Executive Vice President and Chief Financial Officer, effective February 5, 2020.
- Business Wire
AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON™ Atherectomy System
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the PATHFINDER I: Post-Market Registry (PATHFINDER I-Registry, EX-PAD-05), a pilot study to evaluate the safety and efficacy of the Company’s AURYON Atherectomy System in the treatment of de novo, re-stenotic, and in-stent restenosis (ISR) lesions in infrainguinal arteries of patients with Peripheral Artery Diseases (PAD).
- Thomson Reuters StreetEvents
Edited Transcript of ANGO earnings conference call or presentation 7-Jan-20 1:00pm GMT
Q2 2020 AngioDynamics Inc Earnings Call
- Zacks
Here's Why You Should Hold on to AngioDynamics Stock Now
AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.
- Zacks
AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates
AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.
- American City Business Journals
AngioDynamics' latest acquisition will boost $95 million business line
It is the latest in a string of acquisitions for AngioDynamics as chief exec Jim Clemmer refocuses the medical device maker by "carving out significant space in larger and faster growing markets."
- Zacks
AngioDynamics (ANGO) Beats Q2 Earnings Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200.00% and -2.61%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
AngioDynamics Reports Fiscal 2020 Second Quarter Financial Results
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the second quarter of fiscal year 2020, which ended November 30, 2019.
- Business Wire
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Sr. Vice President, General Counsel, and Interim Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:00 a.m. PT on Thursday, January 16, 2020 in San Francisco, CA.
- Simply Wall St.
Should You Worry About AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Pay?
Jim Clemmer has been the CEO of AngioDynamics, Inc. (NASDAQ:ANGO) since 2016. This report will, first, examine the CEO...
- Zacks
Earnings Preview: AngioDynamics (ANGO) Q2 Earnings Expected to Decline
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Do Hedge Funds Love AngioDynamics, Inc. (ANGO)?
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- American City Business Journals
Federal tax repeal equals research boost, more stability for AngioDynamics
The controversial excise tax was suspended in 2018 after AngioDynamics paid nearly $12 million over four years.
- American City Business Journals
Angio hires Fingerpaint to help bring new laser to market
The Albany region's largest medical device maker is teaming up with the area's largest advertising firm for the first time.
- GuruFocus.com
Weekly CEO Buys Highlight
CEO buys this past week include OPKO Health, Eli Lilly and Co., Wesbanco, AngioDynamics and TherapeuticsMD Continue reading...
- Simply Wall St.
Introducing AngioDynamics (NASDAQ:ANGO), The Stock That Dropped 27% In The Last Year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
- Zacks
Why Is AngioDynamics (ANGO) Up 0.9% Since Last Earnings Report?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Insider Monkey
Is AngioDynamics, Inc. (ANGO) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
- Benzinga
The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 22) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...
- American City Business Journals
AngioDynamics' CFO will leave company
The company has undergone a $100 million turnaround since CEO Jim Clemmer and CFO Michael Greiner joined the business a little more than three years ago.
